Barbara Ryan Sells 1,300 Shares of MiNK Therapeutics (NASDAQ:INKT) Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Barbara Ryan sold 1,300 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $15.40, for a total transaction of $20,020.00. Following the sale, the director directly owned 20,406 shares in the company, valued at approximately $314,252.40. This trade represents a 5.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Barbara Ryan also recently made the following trade(s):

• On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.17, for a total transaction of $2,034.00.
• On Monday, March 2nd, Barbara Ryan sold 100 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.83, for a total transaction of $1,083.00.
• On Friday, February 27th, Barbara Ryan sold 400 shares of MiNK Therapeutics stock. The shares were sold at an average price of $10.86, for a total transaction of $4,344.00.

MiNK Therapeutics Trading Down 2.7%

Shares of INKT stock traded down $0.28 during trading on Friday, reaching $10.00. 40,226 shares of the company’s stock traded hands, compared to its average volume of 343,816. The firm’s 50-day moving average is $11.57 and its 200 day moving average is $12.74. The company has a market capitalization of $46.91 million, a P/E ratio of -3.28 and a beta of 0.35. MiNK Therapeutics, Inc. has a 1 year low of $6.34 and a 1 year high of $76.00.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned 0.55% of MiNK Therapeutics at the end of the most recent quarter. Institutional investors own 2.87% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.